Attovia Therapeutics (ATTO) grants CFO 140,000 stock options expiring 2036
Rhea-AI Filing Summary
Attovia Therapeutics, Inc. reported a grant of stock options to its Chief Financial Officer. The grant covers 140,000 Stock Options (Right to Buy) with an exercise price of $17.00 per share, expiring on August 3, 2036, and represents 140,000 options held after the transaction. The options relate to an equivalent number of shares of common stock.
According to the vesting terms, 25% of the options will vest on August 4, 2027, with the remaining options vesting in equal monthly installments over the following 36 months, contingent on continued service to the company.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Attovia Therapeutics, Inc.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) F1 | 140,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 140,000 shares (Direct)
Footnotes (1)
- F1. 25% of the options shall vest on August 4, 2027 and the remaining options shall vest in equal monthly installments over the following 36 months, subject to continued service to the Issuer through such dates.
Key Figures
Options granted: 140,000 options
Exercise price: $17.00 per share
Options after transaction: 140,000 options
+3 more
6 metrics
Options granted
140,000 options
Stock Option (Right to Buy) granted on 2026-08-04
Exercise price
$17.00 per share
Conversion or exercise price of the stock options
Options after transaction
140,000 options
Total stock options held following the reported grant
Initial vesting date
August 4, 2027
25% of the options vest on this date
Remaining vesting period
36 months
Remaining 75% vests in equal monthly installments
Option expiration
August 3, 2036
Expiration date of the stock options
Key Terms
Stock Option (Right to Buy), exercise price, vesting, expiration date
4 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price of $17.0000 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"25% of the options shall vest on August 4, 2027 and the remaining options"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
expiration date financial
"expiration_date: 2036-08-03"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What equity award was reported in Attovia Therapeutics (ATTO) latest Form 4?
The filing reports a grant of 140,000 stock options to the Chief Financial Officer. These options have an exercise price of $17.00 per share and are exercisable for 140,000 shares of Attovia Therapeutics common stock.
What is the exercise price of the new stock options at Attovia Therapeutics (ATTO)?
The newly granted stock options carry an exercise price of $17.00 per share. Each option represents the right to buy one share of common stock at this price, subject to the vesting schedule and continued service conditions.
When do the newly granted Attovia Therapeutics (ATTO) options vest?
The options vest over time: 25% vest on August 4, 2027. The remaining 75% vest in equal monthly installments over the subsequent 36 months, provided the officer continues to serve the company during this period.
What is the expiration date of the Attovia Therapeutics (ATTO) stock options reported?
The stock options granted to the Chief Financial Officer expire on August 3, 2036. After this expiration date, any unexercised options will no longer be exercisable for Attovia Therapeutics common stock.
How many Attovia Therapeutics (ATTO) options does the reporting officer hold after this Form 4 transaction?
Following this grant, the reporting officer holds 140,000 stock options as reported. These options are held directly and are subject to the specified vesting schedule and a $17.00 exercise price per share.